Should you get the new RSV vaccine — and who is eligible in Europe?
Respiratory Syncytial Virus (RSV) can cause serious lower respiratory infections, particularly in older adults and vulnerable groups. In this episode, we explain how the new RSV vaccines work, current eligibility guidance in Europe, and when vaccination may be recommended.
You’ll learn:
• What RSV is and how it affects the lungs and airways
• Who is at higher risk: adults over 60, people with chronic heart or lung disease, and immunocompromised individuals
• How the RSV vaccine stimulates immune protection against severe infection
• Differences between infant RSV prevention strategies and adult vaccination
• Possible side effects and safety monitoring
• When vaccination timing may be influenced by medical history or concurrent illness
• Situations where vaccination may be deferred following clinical assessment
We also clarify how RSV differs from influenza and COVID-19 and why seasonal respiratory protection matters.
This episode complements our full clinical guide:
Should You Get The New RSV Vaccine?
https://www.mobidoctor.eu/blog/should-you-get-the-new-rsv-vaccine
Mobi Doctor provides online medical consultations across Europe. Vaccination advice is based on individual risk assessment and current clinical recommendations.
